William Blair analyst Tim Lugo initiates coverage on Lyra Therapeutics (NASDAQ: LYRA) with an Outperform rating.The analyst commented, "Lyra is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE